Nibrozetone

Adam Zamecnik @a_zamecnik The UK has rejoined EU’s Horizon Europe science research programme. Image Credit: Shutterstock / vlastas The UK has re-joined the EU’s Horizon Europe science research programme after the country’s post-Brexit absence and long-stalled talks. British scientists will now be able to apply for grants and bids to take part in Horizon Europe projects, based on the UK Government’s 7 September announcement. Recommended Reports Reports LOA and PTSR Model - RRX-001 in Gliosarcoma GlobalData Reports State of the Biopharmaceutical Industry 2022 GlobalData View all As an EU member state at the time, the UK was part of the EU’s past Horizon 2020 research funding programme. This programme has since been succeeded by Horizon Europe, which uses its budget of €95.5bn to support research across the region. The programme not only offers funding for research but also provides a chance for collaboration across Europe and beyond such as Armenia, Israel, and New Zealand. “The UK’s decision to re-join the Horizon Europe funding programme will be welcomed warmly by researchers across the EU and Great Britain today,” said Dr Harshil Pate, head of scientific development at Seqera Labs after the announcement. “Tackling the many challenges facing humanity in the 21st century requires international collaboration that sees past borders, uniting our innovative research sectors to improve human health through cutting-edge discoveries in RNA vaccines, DNA analysis and more.” Whilst the UK was initially supposed to be a part of the programme as an associate, its membership was halted by disagreements with the EU over the future of trade rules in Northern Ireland. While a breakthrough in the Northern Ireland talks opened the possibility of readmission , the process faced further delays as reported by outlets at the time. However, the country has now re-joined the scheme and will be a fully associated member of the programme until it concludes in 2027, based on the 7 September announcement . The UK will start financially supporting the Horizon Europe scheme only in January 2024. Furthermore, the UK will also have a new automatic clawback that gives it compensation rights in case that British scientists receive less funding from the programme than what the country will invest. The European Commission estimates that the UK will pay almost €2.6bn per year for its participation in Horizon Europe and the Copernicus earth observation programme, which the country will also rejoin, based on a 7 September European Commission press release. However, the country will not rejoin the EU’s atomic Euratom programme. “We have worked with our EU partners to make sure that this is the right deal for the UK, unlocking unparalleled research opportunities, and also the right deal for British taxpayers,” said UK Prime Minister Rishi Sunak in the statement. The political agreement must now be approved by the European Council before being formally adopted in the EU-UK Specialised Committee on Participation in Union Programmes, per the European Commission’s statement.

-New USAN name, a shortening of its chemical name, signifies a novel therapeutic class -Novel generic name highlights the anti-inflammatory, anticancer, and antioxidant properties of RRx-001 and its potential to address several diverse unmet therapeutic needs TORREY PINES, Calif., July 6, 2023 /PRNewswire/ -- EpicentRx, Inc., a clinical stage biotechnology company with two therapeutic platforms that address cancer and inflammatory diseases, today announced that the United States Adopted Name (USAN) Council in consultation with the World Health Organization's (WHO) International Nonproprietary Names (INN) Expert Committee has assigned the generic name "nibrozetone", a shortening of the chemical name, alpha-bromodinitroazetidine, for its lead drug candidate, RRx-001. This is the first representative of a novel class of hypoxia-activated therapeutics with a chemical scaffold, a dinitroazetidine, that is commonly found only in explosives. RRx-001 is protective under normal oxygen conditions but under low oxygen conditions that are present in tumors the molecule transforms to metabolites that disrupt the tumor microenvironment. RRx-001 is under development for the treatment of small cell lung cancer (SCLC) in a Phase 3 clinical trial, and a soon-to-start late-stage trial for the protection against oral mucositis in first line head and neck cancer, an indication for which RRx-001 has received FDA Fast Track designation. RRx-001 is proprietary to EpicentRx with issued and currently pending patents that are expected to extend coverage until 2042. "We are pleased but not surprised given its unique aerospace-derived origins and dual mechanism of action that USAN has recognized the first-in-class nature of RRx-001 with a new generic name," stated EpicentRx's CEO Dr. Tony Reid. "This is on the critical path for bringing a new drug to market and comes at an opportune time for EpicentRx given the late-stage trials with RRx-001 in SCLC, head and neck cancer, and radioprotection." A nonproprietary name also known as a generic name is necessary and important, according to WHO, for "clear identification, safe prescription and dispensing of medicines to patients, and for communication and exchange of information among health professionals and scientists worldwide". To prevent potentially lethal clinical mix-ups, this name must be distinctive enough to clearly differentiate it from other medications. A multisyllabic mouthful, the chemically descriptive—and distinctive— nibrozetone is unlikely to be confused with other drug names. Therefore, and henceforth, EpicentRx will use "nibrozetone" in upcoming publications, press releases, forums, conferences, and other events or activities on the way to commercialization at which time, hopefully, a more mellifluous and shorter proprietary brand name will replace it. About EpicentRx, Inc. EpicentRx Incorporated is a privately held biopharmaceutical company with two innovation-driven platforms, of which RRx-001 and AdAPT-001 are the lead compounds, respectively. The company's mission, vision and strategy are to discover and develop novel, well-tolerated therapies that target a diverse range of unmet needs in in cancer and non-cancer indications. RRx-001, a dual mechanism small molecule, is designed and currently under clinical investigation to preferentially target diseased tissues like tumors even as it shields normal cells from harm. It is in a Phase 3 trial called REPLATINUM for the treatment of small cell lung cancer (SCLC). A soon-to-start trial is KEVLARx for protection against chemoradiation-induced oral mucositis in first line head and neck cancer. Media Contact Oliwia Barteczko (908) 234-9900 SOURCE EpicentRx, Inc.